Does Affinity Health Plan Cover Forteo?

Understanding Affinity Health Plan and Its Current Status

Affinity Health Plan was a New York-based Medicaid managed care organization that served members primarily in the New York City metropolitan area. Molina Healthcare acquired Affinity Health Plan in 2014, and the plan now operates as Molina Healthcare of New York. If you currently hold a card that says "Affinity Health Plan," your benefits are administered by Molina.

Why the Name Change Matters for Your Coverage

The distinction is not just administrative. Molina Healthcare maintains its own pharmacy formulary, prior authorization criteria, and utilization management protocols. Any coverage lookup for Forteo should reference the current Molina Healthcare of New York formulary rather than legacy Affinity documents.

Where to Verify Your Specific Benefits

Call the member services number on your insurance card or log into the Molina Healthcare member portal. Ask specifically about teriparatide (the generic name for Forteo) and request the drug's tier placement, prior authorization requirements, and any step therapy protocols. Formularies change at least annually, so a 2025 formulary may differ from the current 2026 version.

What Is Forteo and Who Needs It?

Forteo (teriparatide) is a synthetic form of parathyroid hormone (PTH 1-34) that stimulates new bone formation. The FDA approved it in November 2002 for postmenopausal women and men with osteoporosis at high fracture risk [1]. Unlike bisphosphonates, which slow bone breakdown, teriparatide actively builds new bone. That anabolic mechanism makes it a second-line agent reserved for patients with severe disease.

Clinical Evidence for Teriparatide

The Fracture Prevention Trial (N=1,637) demonstrated that teriparatide 20 mcg daily reduced new vertebral fractures by 65% and nonvertebral fractures by 53% compared with placebo over a median of 21 months [2]. The VERO trial (N=1,360) later showed teriparatide was superior to risedronate in reducing new vertebral fractures (5.4% vs. 12.0%, P<0.0001) over 24 months in postmenopausal women with severe osteoporosis [3].

FDA-Approved Indications

Teriparatide carries four specific indications: postmenopausal osteoporosis with high fracture risk, male osteoporosis with high fracture risk, glucocorticoid-induced osteoporosis, and osteoporosis associated with sustained systemic glucocorticoid therapy. The maximum treatment duration is 24 months. This limit stems from preclinical rat studies that showed osteosarcoma risk with prolonged exposure, though a post-marketing surveillance study (the OSTEOSARCOMA study) found no increased osteosarcoma signal in human patients over a 15-year observation period [4].

How Medicaid Managed Care Plans Handle Forteo Coverage

Medicaid managed care plans in New York, including Molina Healthcare of New York (formerly Affinity), follow state pharmacy benefit guidelines with plan-specific modifications. Forteo is classified as a specialty medication on nearly every managed Medicaid formulary in the state.

Prior Authorization Requirements

Prior authorization for teriparatide on Medicaid managed care plans typically requires all of the following: a confirmed diagnosis of osteoporosis via dual-energy X-ray absorptiometry (DXA) with a T-score of -2.5 or below, documentation of at least one fragility fracture or very high FRAX score, trial and failure (or documented intolerance or contraindication) of at least one oral bisphosphonate (usually alendronate), and prescribing by or in consultation with an endocrinologist or rheumatologist [5].

The American Association of Clinical Endocrinologists (AACE) 2020 guidelines state: "Anabolic therapy should be considered as initial therapy in patients with very high fracture risk, including those with recent fractures, fractures while on approved osteoporosis therapy, multiple fractures, or very low T-scores" [6]. This guideline language can support prior authorization appeals for patients who meet "very high risk" criteria even without a bisphosphonate trial.

Step Therapy Protocols

Most plans enforce a step therapy sequence. The standard pathway looks like this:

1. Step 1 (first-line): oral bisphosphonate (alendronate 70 mg weekly or risedronate 35 mg weekly) for at least 12 months
2. Step 2 (second-line): IV bisphosphonate (zoledronic acid 5 mg annually) or denosumab 60 mg every 6 months if oral bisphosphonate fails or is contraindicated
3. Step 3 (third-line): anabolic agent (teriparatide or abaloparatide) if the patient fractures on or cannot tolerate Step 1 and Step 2 agents

Some plans allow skipping directly to Step 3 if the patient presents with multiple vertebral fractures or a hip fracture with a T-score below -3.0. Document everything.

Expected Out-of-Pocket Costs for Forteo

The retail price for a 28-day Forteo pen is approximately $3,900 without insurance. With Medicaid managed care coverage, out-of-pocket costs are typically minimal.

Medicaid Copay Structures

New York Medicaid managed care plans cap pharmacy copays. For most Medicaid members, specialty drug copays range from $0 to $3 per prescription depending on the specific plan and drug tier. If you are a dual-eligible member (Medicare plus Medicaid), your cost-sharing may follow Medicare Part D rules instead, which can be substantially higher for specialty-tier drugs.

Manufacturer Assistance Programs

Eli Lilly offers the Forteo Savings Card for commercially insured patients, but this program does not apply to Medicaid or Medicare beneficiaries. Medicaid members who face coverage denials should contact Eli Lilly's Lilly Cares Foundation, which provides free medication to qualifying patients with household incomes at or below 400% of the federal poverty level [7].

Biosimilar Option: Teriparatide-TEVA

The FDA approved a teriparatide biosimilar in 2023. Biosimilar teriparatide may appear on Molina formularies at a lower tier or with fewer restrictions than brand Forteo. Ask your prescriber and pharmacist whether the biosimilar is available on your plan's formulary, as this can reduce both copays and prior authorization burden.

What to Do If Forteo Coverage Is Denied

A coverage denial is not the end of the process. Medicaid managed care plans in New York must provide written denial notices with appeal instructions, and members have the right to internal and external appeals.

Internal Appeal Process

File a written appeal within 60 days of the denial. Include supporting clinical documentation: DXA scan results, fracture imaging, a letter of medical necessity from your prescriber, and records showing prior bisphosphonate use and failure. Reference the AACE 2020 guidelines and the Endocrine Society's 2019 clinical practice guideline on pharmacological management of osteoporosis [8].

External Review and Fair Hearing

If the internal appeal is denied, New York Medicaid members can request a Fair Hearing through the New York State Office of Temporary and Disability Assistance. You can also request an expedited review if your physician certifies that delay poses imminent risk of fracture or serious harm.

Peer-to-Peer Review

Many plans offer peer-to-peer review, where your prescribing physician speaks directly with the plan's medical director. This step often resolves denials faster than written appeals. The Endocrine Society guideline recommends teriparatide as initial therapy for patients at "very high fracture risk," defined as a recent fracture within the past 12 months, fractures on existing therapy, multiple fractures, fractures while on osteoporosis drugs, or T-scores below -3.0 [8]. Having your physician quote this guideline during peer review can be effective.

Alternative Osteoporosis Medications if Forteo Is Not Covered

If Forteo coverage proves unattainable, several alternative agents are available with varying formulary placements.

Oral and IV Bisphosphonates

Generic alendronate costs as little as $4 per month and is covered on virtually every formulary without prior authorization. Zoledronic acid (Reclast), given as a once-yearly IV infusion, showed a 70% reduction in vertebral fracture risk and a 41% reduction in hip fracture risk in the HORIZON-PFT trial (N=7,765) [9]. Zoledronic acid typically requires prior authorization but sits at a lower specialty tier than teriparatide.

Denosumab (Prolia)

Denosumab 60 mg subcutaneous injection every 6 months is an anti-RANKL antibody that reduces vertebral, hip, and nonvertebral fractures. The FREEDOM trial (N=7,868) showed a 68% reduction in vertebral fractures over 3 years compared with placebo [10]. Denosumab is usually Tier 3 or Specialty Tier on Medicaid formularies. One consideration: discontinuing denosumab causes rapid bone loss and a rebound increase in vertebral fracture risk, so patients must transition to a bisphosphonate if denosumab is stopped [11].

Abaloparatide (Tymlos)

Abaloparatide is another anabolic agent (a PTHrP analog) that works through a similar mechanism to teriparatide. The ACTIVE trial (N=2,463) demonstrated an 86% reduction in new vertebral fractures versus placebo over 18 months [12]. Abaloparatide may have different formulary placement than Forteo on your plan. Some plans cover one anabolic agent but not the other, so check both.

Romosozumab (Evenity)

Romosozumab is a sclerostin inhibitor with both anabolic and antiresorptive effects. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced clinical fracture risk by 27% compared with alendronate alone over a median of 33 months [13]. Romosozumab carries a cardiovascular warning and is limited to 12 monthly doses. Coverage varies widely across Medicaid plans.

How to Get the Fastest Approval for Forteo

Speed matters when you have active fractures or very high fracture risk. A structured approach can reduce the time from prescription to injection.

Prepare Documentation Before Prescribing

Gather DXA results, fracture imaging, and a complete medication history documenting bisphosphonate trial dates and outcomes before your physician submits the prior authorization. Missing documentation is the most common reason for delays.

Use the Correct Diagnosis Codes

The ICD-10 codes that best support teriparatide authorization include M80.08XA (age-related osteoporosis with current pathological fracture), M80.00XA (age-related osteoporosis with current pathological fracture, unspecified site), and M81.0 (age-related osteoporosis without current pathological fracture). Fracture codes carry more weight than osteoporosis-without-fracture codes.

Request Expedited Review When Appropriate

If your physician documents that standard review timelines (typically 14 business days for Medicaid) could result in harm, request an expedited review. Expedited decisions must be rendered within 72 hours under New York Medicaid rules. A recent vertebral fracture or a fall with high re-fracture risk qualifies.

Understanding Teriparatide Treatment Duration and Monitoring

Forteo treatment is limited to 24 months. This fixed duration affects how coverage decisions interact with treatment planning.

Monitoring During Treatment

The Endocrine Society recommends checking serum calcium within the first month of teriparatide therapy. Hypercalcemia occurs in approximately 11% of patients but is usually mild and transient [8]. Bone turnover markers (P1NP or osteocalcin) can be measured at 1 to 3 months to confirm anabolic response. A DXA scan at 12 to 24 months documents treatment effect.

Transition After Teriparatide

Bone density gains from teriparatide are lost rapidly if no antiresorptive agent follows. The DATA-Switch trial showed that women who received denosumab after teriparatide continued to gain bone density, while those who received placebo lost gains within 12 months [14]. Your post-teriparatide plan should include an antiresorptive drug. Confirm that the follow-on medication (bisphosphonate or denosumab) is also covered by your plan before starting Forteo.

The 2020 AACE guideline recommends: "Following completion of anabolic therapy, treatment with an antiresorptive agent is recommended to maintain BMD gains" [6]. Build this transition into the prior authorization request itself so coverage for the sequential agent is pre-approved.